Skip to main content

Compugen, Premier Biosoft

Premium
Compugen this week introduced the Viral Peptides Discovery Platform for the identification of peptides from viral genomes for potential therapeutic use against inflammatory and immune-related diseases.
 
The company said the platform has been validated and led to the discovery of two novel viral peptides that have demonstrated the ability to suppress inflammatory response in in vitro studies.
 
Using algorithms and in silico tools that predict a large number of potential natural peptides produced by viruses, the platform chooses those peptides that show potential anti-inflammatory activities.
 

 
Premier Biosoft this week launched SimGlycan version 2.6.
 
The MS/MS data analysis software now annotates mass spectra, showing the loss of successive monosaccharides with each peak, “enabling better glycan visualization and outputting publication quality graphics of the results,” the company said in a statement.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.